Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2016-01-19 Director's Dealing
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Correction: Director Share Purchases
Director's Dealing Classification · 1% confidence The document is a regulatory announcement identified by the 'RNS Number' header and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content explicitly details share purchases made by company Directors ('Director Share Purchases') and lists the number of shares held by each director after the transaction. This directly corresponds to the definition of Director's Dealing (insider trades). Although it is an RNS filing, the specific nature of the content points to the more precise 'DIRS' code over the general 'RNS' fallback.
2016-01-19 English
Director Share Purchases
Director's Dealing Classification · 1% confidence The document is a regulatory announcement identified by the 'RNS Number' and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content explicitly details 'Director Share Purchases' and lists the number of shares purchased by specific directors (Barry Clare, Stephen Franklin, John Bradshaw) and their resulting holdings. This directly corresponds to the definition of Director's Dealing (insider trades). Therefore, the appropriate filing type code is DIRS.
2016-01-19 English
Exercise of Options
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly labeled with an "RNS Number" and contains information about the issuance of new ordinary shares following an option exercise. This type of announcement, which details changes in the total number of voting rights and is distributed via the London Stock Exchange's news service (RNS), typically falls under general regulatory announcements or specific share/capital changes. Since the core event is the issuance of new shares and the resulting change in total voting rights, it strongly relates to capital structure changes. However, the presence of the RNS header and the nature of the announcement (a short update distributed via the exchange news service) suggests it is a general regulatory filing. Given the options, 'Share Issue/Capital Change' (SHA) is highly relevant due to the issuance of 272,000 new shares. Alternatively, 'Regulatory Filings' (RNS) is the general category for RNS-distributed news. Since the content is specifically about the issuance of shares and the resulting total voting rights, SHA is the most precise fit, as it details a change in the capital structure, even if distributed via RNS.
2016-01-11 English
Appoints Chief Medical Officer
Board/Management Information Classification · 1% confidence The document is a formal announcement released via RNS (RNS Number : 6374K) on January 4, 2016. The core content is the announcement of the appointment of a new Chief Medical Officer (Dr Hamina J Patel). This directly relates to changes in senior management personnel. Based on the definitions, this falls under 'Board/Management Information' (Code: MANG). Although it is distributed via RNS, the specific content is about management change, making MANG the most precise classification over the general RNS fallback.
2016-01-04 English
Half Yearly Report
Interim / Quarterly Report Classification · 1% confidence The document is a 'Half Yearly Report' for Evgen Pharma PLC for the period ended 30 September 2015. It contains detailed financial results, including a net loss statement, cash position, and a comprehensive 'Chairman's and Chief Executive's Statement' discussing business operations, pipeline updates, and strategy. Since it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2015
2015-12-07 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled with "RNS Number : 6432H" and contains the header "TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES". This format is characteristic of regulatory notifications concerning changes in significant shareholdings, which aligns with the definition for Major Shareholding Notification (MRQ). Although RNS is mentioned as the service provider, the content itself is a specific regulatory filing about share ownership changes, not just a general announcement of a report's publication (RPA/RNS). Therefore, MRQ is the most precise classification.
2015-12-01 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.